Autoantibody and IFN Burden Correlate With Nipocalimab Response in Sjögren's DiseaseByR. Hal Scofield, MDJune 10th 2026
Nerandomilast Slows Lung Function Decline, Reduces Mortality Risk in Autoimmune ILD SubgroupByPatrick CampbellJune 10th 2026
OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhDByXenofon Baraliakos, MD, PhDJune 8th 2026
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-HeadByPhilip J. Mease, MDJune 8th 2026
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA StudyByXenofon Baraliakos, MD, PhDJune 6th 2026